AbbVie
ABBV
$248.76
-0.53%
AbbVie is a global biopharmaceutical company focused on immunology, oncology, neuroscience, and aesthetics, with key products including Skyrizi, Rinvoq, Humira, and Botox. As a top-tier player in the pharmaceutical industry, it leverages a diversified portfolio and a robust pipeline, reinforced by strategic acquisitions such as Allergan, Cerevel, and ImmunoGen. The current investor narrative centers on AbbVie's successful post-Humira transition, driven by the rapid growth of Skyrizi and Rinvoq, alongside pipeline advancements in weight-loss and eczema treatments and the recent $10.9 billion Apogee acquisition, which has fueled a stock rally to new 52-week highs. However, debates persist regarding valuation sustainability and the long-term impact of patent expirations and FDA setbacks.…
ABBV
AbbVie
$248.76
Related headlines
Investment Opinion: Should I buy ABBV Today?
Rating: Buy. AbbVie offers a compelling risk/reward with a forward PE of 14.9x (32% below industry average), accelerating revenue growth (12.4% YoY), and a strong pipeline. Analyst consensus is Buy with an average target of $272.18, implying 11.6% upside. The stock is undervalued relative to peers and its own history.
Sign up to view all
ABBV 12-Month Price Forecast
The AI model assesses ABBV as bullish given its valuation discount, strong growth, and pipeline momentum. However, confidence is medium due to earnings volatility and regulatory risks. An upgrade to high confidence would occur if forward PE remains below 15x and revenue growth sustains above 10%. A downgrade would be triggered by a major pipeline failure or a significant drop in Skyrizi/Rinvoq sales.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on AbbVie's 12-month outlook, with a consensus price target around $275.39 and implied upside of +10.7% versus the current price.
Average Target
$275.39
0 analysts
Implied Upside
+10.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$200 - $328
Analyst target range
AbbVie is covered by 28 analysts, with a consensus recommendation of 'Buy' (mean rating 1.74) and an average target price of $272.18, implying an upside of 11.6% from the current price of $243.87. The sentiment is bullish, with 10 recent ratings from major firms (UBS, BMO, Wells Fargo, etc.) all maintaining positive or neutral stances, and no downgrades. The target price range spans from $200 (low) to $328 (high), with the high target assuming successful pipeline execution and continued growth of Skyrizi/Rinvoq, while the low target reflects risks from patent cliffs and FDA setbacks. The wide spread of $128 indicates moderate uncertainty, but the overall bullish consensus and recent price momentum suggest analysts are confident in AbbVie's long-term growth story.
Drowning in data?
Find the real signal!
Bulls vs Bears: ABBV Investment Factors
AbbVie presents a compelling bull case with accelerating revenue growth, a discounted forward valuation, and a robust pipeline. However, the bear case highlights earnings distortion, high leverage, and regulatory risks. Currently, the bull side has stronger evidence, as the forward PE and analyst targets suggest undervaluation. The key tension is whether the market's optimism on Skyrizi/Rinvoq and pipeline success justifies the premium, or if patent cliffs and FDA issues will derail growth. The resolution of this tension will determine the stock's trajectory.
Bullish
- Skyrizi and Rinvoq driving growth: Q1 2026 revenue grew 12.4% YoY to $15.0B, with Skyrizi ($4.48B) and Rinvoq ($2.12B) more than offsetting Humira's decline ($0.69B). This demonstrates a successful post-Humira transition.
- Forward PE at 32% discount to peers: Forward PE of 14.9x is well below the industry average of 22x, suggesting undervaluation relative to peers. Historically, the forward PE has ranged 10-20x, and current levels are near the lower end.
- Strong free cash flow and dividend: TTM free cash flow of $20.9B comfortably covers the dividend (yield 2.87%) and acquisitions. The payout ratio of 275.8% is elevated due to one-time charges, but normalized earnings support sustainability.
- Analyst consensus Buy with 11.6% upside: 28 analysts rate ABBV a Buy (mean 1.74) with an average target of $272.18, implying 11.6% upside. Recent ratings from major firms are positive, with no downgrades.
Bearish
- Elevated trailing PE due to charges: Trailing PE of 96.4x is distorted by acquisition-related charges, but it signals earnings volatility. Q1 2026 net income of $699M was depressed, with a net margin of only 4.7%.
- High debt and negative equity: Debt-to-equity of -21.1x reflects negative equity from buybacks, and the current ratio of 0.67 indicates tight liquidity. While cash flow is strong, leverage increases financial risk.
- Patent cliff and FDA setbacks: Humira's decline continues, and the FDA rejection for TrenibotE on manufacturing issues highlights regulatory risk. Future patent expirations could pressure revenue.
- Recent price momentum may limit upside: Stock is trading at 91% of its 52-week range, near highs. The 1-month relative strength is -7.0%, suggesting short-term overextension and potential consolidation.
ABBV Technical Analysis
AbbVie's stock has demonstrated a robust long-term uptrend, with a 1-year price change of +24.23%, significantly outperforming the S&P 500's +21.46% over the same period. The current price of $243.87 sits at approximately 91% of the 52-week range (low $190.75, high $267.47), indicating the stock is trading near its highs, reflecting strong momentum but also potential overextension. This positioning suggests investor confidence in the company's growth trajectory, though it may limit near-term upside without consolidation.
Beta
0.28
0.28x market volatility
Max Drawdown
-19.2%
Largest decline past year
52-Week Range
$191-$267
Price range past year
Annual Return
+25.2%
Cumulative gain past year
| Period | ABBV Return | S&P 500 |
|---|---|---|
| 1m | +0.3% | +3.1% |
| 3m | +18.0% | +3.3% |
| 6m | +7.5% | +13.3% |
| 1y | +25.2% | +20.2% |
| ytd | +8.5% | +13.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ABBV Fundamental Analysis
AbbVie's revenue trajectory is robust, with Q1 2026 revenue of $15.0 billion, up 12.4% year-over-year, and a clear acceleration from the 8.5% growth seen in Q4 2025. The growth is driven by Skyrizi ($4.48 billion) and Rinvoq ($2.12 billion), which are offsetting Humira's decline ($0.69 billion), while the aesthetics segment (Botox Cosmetic $0.67 billion) remains stable. This diversification supports a positive outlook, though reliance on a few key products remains a risk. The company's profitability is solid, with a gross margin of 71.9% in Q1 2026, up from 70.0% in the prior year, and an operating margin of 31.6%, reflecting efficient cost management. Net income of $699 million in Q1 2026 was impacted by one-time charges, but the trailing twelve-month net margin of 6.9% indicates normalized profitability. The balance sheet shows a high debt-to-equity ratio of -21.1 (due to negative equity from buybacks), but the company generates strong free cash flow of $20.9 billion TTM, covering dividends and acquisitions. The current ratio of 0.67 suggests tight liquidity, but the robust cash flow and access to capital markets mitigate near-term risk.
Quarterly Revenue
$15.0B
2026-03
Revenue YoY Growth
+12.4%
YoY Comparison
Gross Margin
71.9%
Latest Quarter
Free Cash Flow
$20.9B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ABBV Overvalued?
Given AbbVie's positive net income, the PE ratio is the primary valuation metric. The trailing PE of 96.4x is elevated due to depressed earnings from acquisition-related charges, while the forward PE of 14.9x reflects expected earnings normalization and growth, implying the market anticipates a significant earnings rebound. Compared to the industry average PE of 22x, AbbVie's forward PE of 14.9x represents a 32% discount, suggesting the stock is undervalued relative to peers, which may be justified by its strong growth prospects and dividend yield of 2.87%. Historically, AbbVie's forward PE has ranged from 10x to 20x over the past five years, and the current 14.9x sits near the lower end of that range, indicating a value opportunity relative to its own history, especially given the company's accelerating revenue growth and pipeline momentum.
PE
96.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 15x~139x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
26.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a high debt load (debt-to-equity -21.1x) and negative equity from aggressive buybacks, which could limit financial flexibility. The current ratio of 0.67 indicates potential liquidity stress, though strong FCF of $20.9B mitigates near-term concerns. Earnings are volatile due to acquisition charges, as seen in Q1 2026 net income of $699M and a trailing PE of 96.4x, which could spook investors if not normalized quickly. Revenue concentration in Skyrizi and Rinvoq (44% of Q1 revenue) poses a risk if either faces competition or clinical setbacks.